To assess the effect of early detection of papillary non-muscle-invasive bladder cancer with hexaminolevulinate (Hexvix ® ) blue-light cystoscopy on long-term recurrence rates.
• This analysis was a long-term follow-up of participants from a prospective, randomized, multi-center study 1 .
• The initial study enrolled 779 patients with suspected Ta/T1 bladder tumors that were considered at increased risk for recurrence. They were treated in one of 19 centers in the US and Canada or at one of 9 centers in Europe.
• Patients were randomized to one of two treatment groups:
• White light group, in which patients underwent cystoscopy and mapping of bladder lesions using white light, followed by transurethral resection of the bladder (TURB) where indicated (n=280).
• Hexvix® group, in which patients underwent cystoscopy and mapping of bladder lesions with white light. Patients in this group were then further randomized to either:
• Discontinue study involvement.
• Undergo a second bladder mapping using Hexvix® blue-light cystoscopy, followed by TURB under white and blue-light, to detect additional lesions and assess completeness of resection (n=271).
• Following institutional review board approval, long-term follow-up data were retrospectively obtained from 516 patients at 25 of the centers. • 261 (93%) patients from the white-light group and 255 (94%) from the Hexvix® group.
• Median follow-up was 53.0 months in the white-light group and 55.1 months in the Hexvix® group.
To note: The extension study was not powered to show statistical significance for any clinical parameter.
Summary of primary study results
1
• Significantly improved detection of Ta/T1 tumors was reported using Hexvix® blue-light cystoscopy as an adjunct to white light cystoscopy compared to detection using white light alone (p=0.001).
• In 43% of the 47 patients in whom additional tumors were detected with blue-light cystoscopy, the additional tumors were T1G2, T1G3 or TaG3.
• The difference in recurrence rates between the groups at 9 months was statistically AIM METHODS RESULTS significant (p=0 .026), in favor of the Hexvix® group.
• Fewer patients in the Hexvix® group than in the white light group experienced recurrences of worrisome cancers-e.g. carcinoma in situ (CIS), T1 or T2 (p=0.17).
Figure 1
White light TURB can miss tumors in the bladder, leading to increased recurrence. Hexvix® blue-light cystoscopy, used as an adjunct to white light cystoscopy, allows better detection and therefore better resection of bladder cancer lesions. This results in significantly longer time to recurrence than with white light only cystoscopy and TURB, as well as a trend toward improved bladder preservation. of patients in the Hexvix® group and 32% in the white light group remained tumor free (p=0.14).
• Tumor progression to T2-T4 bladder cancer was reported in 3% of patients in the Hexvix® group and in 6% of those in the white light group (p=0.066).
• The cystectomy rate was 5% in the Hexvix® group and 8% in the white light group (p=0.16).
The intravesical therapy rate was similar in both groups.
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